Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
<p><strong>Background:</strong> Myelofibrosis (MF)-associated constitutional symptoms can severely impact health-related quality of life. Clinical trials in MF traditionally measure symptom response to treatment as a landmark endpoint of total symptom score (TSS) reduction...
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
Wiley
2023
|